|  |  |
| --- | --- |
| MinutesDrug Utilization Review Board MeetingDATE: March 12, 2025 |  |



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting

Meeting opened at 6:00 p.m. by Laura Spring, MD

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Diane Bruessow; Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Colleen Labelle, MSN, RN-BC, CARN; Jaqueline Gagnon; Lori Lewicki, RPh; Mirembe Reed, Pharm.D.; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:** Timothy Fensky, RPh

**Agenda Items:**

* Welcome and Introductory Remarks
* Guest Speakers
* Annual Pipeline Continuing Education Program
* Asthma and Allergy Quality Assurance Analysis
* MHDL Update
* **DUR Operational Update**
* **MassHealth Update**
* **Open Forum**

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| **Guest Speakers** | * Sharl Azar, MD, Director of Sickle Cell Center, spoke on pain treatment options for patients with Sickle Cell Disease.
* Cheryl Juaire, Founder of Teen Sharing Inc., spoke on behalf of patient advocacy for opioid addiction.
 | **Follow-up**Minutes are approved. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| Annual Pipeline Continuing Education Program | Annual Pipeline Continuing Education by Dr. Collin Jerard and Dr. Stephen Alverez This Pipeline update provided an overview of clinical and/or regulatory updates for select pharmaceutical pipeline agents in late-stage development.  | **Follow-up**Informational/Advisory |
| Action | Discussion* Described the current trends in the FDA approval process
* Compared and contrasted emerging pipeline agents with currently available therapeutic options
* Summarized biosimilar product availability of reference agents over the next year
* Reviewed trends in historical approvals of new drugs
* Looked at upcoming Pipeline trends

Conclusions* Oncology drugs continue to lead the pack for pipeline drug development, with no new therapeutic areas cracking the top 10.
* Cell and gene therapy approvals accelerate as the number of clinical trials continue to trend upward.
* There are more than 40 potential biosimilar launches in 2025 across various therapeutic classes.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Asthma and Allergy Quality Assurance (QA)** | Asthma and Allergy Quality Assurance Analysis by Dr. Karen StevensThis analysis of current medical literature provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed current class management
* Discussed consensus guideline updates for various indications
* Evaluated utilization for MassHealth members
* Presented expanded indications for the monoclonal antibodies
* Examined pipeline agents as well as investigational indications for currently available medications
* Summarized recommendations from QA analysis

Conclusions* Approval criteria have been created and added to the MHDL and PA Form for the following expanded indications,
	+ Dupixent® for chronic obstructive pulmonary disease (COPD)
	+ Nemluvio® for atopic dermatitis
	+ Nucala® and Xolair® for chronic rhinosinusitis with nasal polyps. Criteria have been updated to be in line with Dupixent management.
* The asthma and allergy monoclonal antibodies continue to be highly utilized for the approved indications.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Drug List (MHDL) Update** | MHDL Update by Dr. Phuong Luc MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout. | **Follow-up**Informational/Advisory |
| Action | Discussion * Effective April 1, 2025:
	+ There were 14 additions to the MHDL; and
	+ There were two changes in PA status.
* There were several changes to Coverage Status for Prior Authorization Status; Coverage Status; Brand Name Preferred Over Generic List; 90-day Initiative; Updates and Changes to the MHDL.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Update** | MassHealth Update by Dr. Kimberly LenzMassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed current clinical program initiatives
* Provided direct negotiation status update
* Discussed operational updates
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Open Forum** | Open Forum | **Follow-up**Informational/Advisory |

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_